SCHEMBL22952346

SCHEMBL22952346

CCN1CCC2C1CCN2C

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26618041 0.89 CHRM2 (0.39) CHRM2
SCHEMBL27072955 0.84 — —
SCHEMBL22301662 0.84 CHRM2 (0.30) CHRM2
SCHEMBL26945189 0.79 ALDH1A1 (0.36) CHRM2
SCHEMBL26945188 0.79 ALDH1A1 (0.36) CHRM2
SCHEMBL2274680 0.79 ALDH1A1 (0.36) CHRM2
SCHEMBL13751280 0.78 ALDH1A1 (0.37) —
SCHEMBL22318124 0.78 SMN1; SMN2 (0.30) —
SCHEMBL26618049 0.74 CHRM2 (0.41) CHRM2
SCHEMBL13751142 0.72 ALDH1A1 (0.39) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024020084-A1 HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-25 — — WO disclosed
WO-2021022163-A2 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-02-04 — — WO disclosed
Send feedback